文献速递消化系统肿瘤

RAS/RAF野生型结直肠癌对抗表皮生长因子受体治疗的耐药机制因方案和治疗线数而异

Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.
PubMed 文献 · J Clin Oncol · 2022-11-09

该研究分析三项大型随机试验中RAS/BRAF/EGFR野生型转移性结直肠癌患者的配对血浆样本,比较一线EGFRi联合化疗与三线单药EGFRi的获得性突变特征,并建立耐药细胞系进行转录组分析。结果显示单药EGFRi应答者获得性突变发生率46%,联合化疗者仅9%;基线耐药亚克隆突变很少在进展时成为克隆性。结论支持转录组耐药机制在联合化疗时占主导,而单药EGFRi后获得性MAPK突变更普遍。

要点

  • 单药EGFRi应答者获得性突变发生率为46%,联合化疗者为9%。
  • 基线耐药亚克隆突变在进展时很少扩展为克隆性,多数保持亚克隆或消失。
  • 对西妥昔单抗或化疗获得性耐药的临床前模型对另一类 agents 交叉耐药,转录组符合上皮-间质转化。

核心结论

  • 这些发现支持一种耐药模型:在活性细胞毒性化疗联合EGFRi时,转录组耐药机制占主导;单药EGFRi后获得性MAPK突变更普遍。

研究设计与样本

  • 分析三项大型随机试验中RAS/BRAF/EGFR野生型转移性结直肠癌患者的配对血浆样本,这些试验评估一线EGFRi联合化疗及三线单药EGFRi。
  • 评估治疗获得的变异的突变特征。
  • 建立对西妥昔单抗、输注氟尿嘧啶+亚叶酸钙+奥沙利铂及SN38耐药的结直肠癌细胞系,并进行转录组分析。

主要发现

  • 肿瘤经单药EGFRi治疗并应答的患者获得性突变发生率为46%,联合细胞毒性化疗者为9%。
  • 与普遍接受的获得性耐药克隆演化假说相反,基线耐药亚克隆突变很少在进展时扩展为克隆性,多数保持亚克隆或消失。
  • 对西妥昔单抗或化疗获得性耐药的临床前模型对另一类 agents 交叉耐药,转录组谱符合上皮-间质转化。
  • 相比之下,MAPK通路中常见的获得性耐药变异不影响对细胞毒性化疗的敏感性。

临床怎么用

  • 作者认为,该模型对评估以获得性MAPK突变为指导的EGFRi再挑战策略的前瞻性研究有启示,并强调需要解决转录耐药机制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-pathway members. However, this was primarily on the basis of single-agent EGFRi trials and little is known about the resistance mechanisms of EGFRi combined with effective cytotoxic chemotherapy in previously untreated patients. METHODS: We analyzed paired plasma samples from patients with RAS/BRAF/EGFR wild-type metastatic CRC enrolled in three large randomized trials evaluating EGFRi in the first line in combination with chemotherapy and as a single agent in third line. The mutational signature of the alterations acquired with therapy was evaluated. CRC cell lines with resistance to cetuximab, infusional fluorouracil, leucovorin, and oxaliplatin, and SN38 were developed, and transcriptional changes profiled. RESULTS: Patients whose tumors were treated with and responded to EGFRi alone were more likely to develop acquired mutations (46%) compared with those treated in combination with cytotoxic chemotherapy (9%). Furthermore, contrary to the generally accepted hypothesis of the clonal evolution of acquired resistance, we demonstrate that baseline resistant subclonal mutations rarely expanded to become clonal at progression, and most remained subclonal or disappeared. Consistent with this clinical finding, preclinical models with acquired resistance to either cetuximab or chemotherapy were cross-resistant to the alternate agents, with transcriptomic profiles consistent with epithelial-to-mesenchymal transition. By contrast, commonly acquired resistance alterations in the MAPK pathway do not affect sensitivity to cytotoxic chemotherapy. CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Parseghian CM, Sun R, Woods M, et al. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol. 2022. PMID: 36351210. doi:10.1200/JCO.22.01423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。